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Host-pathogen interactionsThanks to the modern sequencing era, the extent to which infectious disease imposes selective pressures
on the worldwide human population is being revealed. This is aiding our understanding of the underlying
immunological and host mechanistic defenses against these pathogens, as well as potentially assisting in
the development of vaccines and therapeutics to control them. As a consequence, the workshop ‘‘How
genomics can be used to understand host susceptibility to enteric infection, aiding in the development
of vaccines and immunotherapeutic interventions” at the VASE 2018 meeting, aimed to discuss how
genomics and related tools could be used to assist Shigella and ETEC vaccine development. The workshop
featured four short presentations which highlighted how genomic applications can be used to assist in
the identification of genetic patterns related to the virulence of disease, or host genetic factors that could
contribute to immunity or successful vaccine responses. Following the presentations, there was an open
debate with workshop attendees to discuss the best ways to utilise such genomic studies, to improve or
accelerate the process of both Shigella and ETEC vaccine development. The workshop concluded by mak-
ing specific recommendations on how genomic research methods could be strengthened and harmonised
within the ETEC and Shigella research communities.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Introduction
Enterotoxigenic Escherichia coli (ETEC) and Shigella remain lead-
ing bacterial causes of diarrhoeal and dysenteric illness in children
of underdeveloped countries, and in individuals who travel to such
endemic areas [1]. There are currently no licenced vaccines against
these enteric pathogens, but the global health community has pri-
oritized their development [1,2]. One way that could improve or
accelerate the process of both Shigella and ETEC vaccine develop-
ment might be to complement classical vaccinology approaches
with the use of genomics and/or related genomic tools.
Genomic studies using both computational and experimental
methods, have significantly advanced our understanding of the
molecular pathogenesis of many microbes. For instance, whole
genome sequencing (WGS)/next-generation sequencing (NGS)can be used to provide an insight into genomic diversity and evo-
lution of different microbial species [3]. Reverse vaccinology meth-
ods can also be used to aid the identification of novel vaccine
antigen candidates against different pathogens [4,5]. Likewise, host
gene expression profiling of disease burdened patients or vaccinees
compared to healthy controls, has enabled the identification of
immunologically related host biomarkers. This systems vaccinol-
ogy approach can be used to inform vaccine efficacy, and the safety
of novel vaccine candidates or immunotherapeutic interventions
[6–8].
When considering the use of genomics, related genomic tech-
nologies and methods should also be considered. Examples
include: transcriptomic analysis of host-pathogen interactions
upon infection or vaccination; proteomic analysis to study
protein-protein interactions within the pathogen or between the
host and pathogen; pathogen and host rapid phenotyping;
immunoproteomic analysis; and data mining of various genomic
or protein databases [7–10]. Such genomic tools are attempting, aiding
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immune responses to natural infection or vaccination, with the
ultimate aim of defining better correlates of protection.
The purpose of this VASE 2018 workshop was to discuss how
genomics and related applications could be applied to facilitate
the development of Shigella and ETEC vaccines. The workshop
began with four short presentations that highlighted how geno-
mics and related tools can successfully be used to aid the identifi-
cation of genetic patterns related to the virulence of disease, or
host genetic factors that could contribute to immunity or success-
ful vaccine responses. The presentations were then followed by an
open workshop debate on the best ways to utilise such genomic
based studies to improve ETEC and Shigella vaccine development.
The workshop concluded by making specific recommendations
on how genomic research methods could be strengthened and har-
monised in the ETEC and Shigella vaccine development fields.2. Summary of the presentations
2.1. FUT2, an association with ETEC infection
Lynda Mottram (University of Gothenburg, Sweden) described
how she has used Genome-wide Association study (GWAS) data
to identify potential human genetic biomarkers of severe ETEC
infection susceptibility/possible ETEC vaccine efficiency [19].
There is evidence to suggest that the human small intestinal
glycan antigen Lewis a (Lea), could be a human intestinal binding
receptor of ETEC colonization factor I (CFA/I), and related colonisa-
tion factor (CF) fimbriae [11,12]. A clinical trial has also previously
demonstrated Lea phenotyped Bangladeshi children are more sus-
ceptible to symptomatic than asymptomatic ETEC CFA/I infection
[13]. The human Lea phenotype (caused by homozygous fucosyl-
transferase 2 [FUT2] single nucleotide polymorphisms [SNPs]) has
also been previously associated with susceptibility to other enteric
infections, as well as lower immunoglobulin A (IgA) antibody
responses to rotavirus vaccination [14,15]. Subsequently the aim
of Dr Mottram’s study was to determine if a FUT2 SNP could also
be used as a human genetic biomarker of susceptibility to severe
ETEC CFA/I and related CFs diarrhoeal disease/and or vaccine effi-
ciency associated with ETEC vaccines containing CFA/I.
Dr Mottram initially searched for the frequency of known FUT2
non-synonymous SNPs in the Bangladeshi population. This was
performed using The 1000 Genomes Project dataset, a large GWAS
open access catalogue of genetic variants (allele frequency [AF]
> 0.01) found in 2,504 human genetic sequences of 26 different
human populations worldwide [16]. Included in this dataset are
86 genetic sequences of healthy adults who live in Dhaka,
Bangladesh.
Consequently, a variant calling file (VCF) from The 1000 Gen-
omes Project server that contained all the FUT2 genetic mutations
(in region FUT2, chromosome 19: Genome Reference Consortium
Human Build 37: 49199228:49209207) identified in the GWAS
studied individuals, was downloaded [16]. The Ensembl allelic AF
calculator was used to predict the total allele count and alternative
allele count of all genetic variants (AF > 0,01) present in each of the
26 worldwide populations [17]. Then, to identify non-synonymous
FUT2 SNPs, a further analysis of The 1000 Genomes Project FUT2
genetic variation dataset was performed using the Ensembl Varia-
tion Effect Predictor (VEP) tool [18]. This analysis of The 1000 Gen-
omes project dataset identified three non-synonymous FUT2 single
nucleotide SNPs candidates, that were present in the Bangladeshi
population [19].
Using RT-PCR SNP genotyping methods, the frequency of these
three FUT2 non-synonymous SNPs in Lea phenotyped Bangladeshi
children, who had been previously clinically monitored for ETECPlease cite this article as: L. Mottram, S. Chakraborty, E. Cox et al., How genomi
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[13,19,20]. This retrospective association study identified two
FUT2 SNPs; rs200157007-TT and rs601338-AA, that were strongly
associated with symptomatic ETEC infection and the Lea phenotype
in the Bangladeshi children [19].
However, potentially due to the limited number of samples
from which human gDNA could be successfully extracted from,
only a trend but not a statistical relationship with rs200157007-
TT and rs601338-AA SNPs, symptomatic ETEC expressing CFA/I or
related CF infection, and the Lea phenotyped Bangladeshi children
could be found. Subsequently, further clinical studies in other ETEC
endemic areas, as well as further in-vivo analysis are needed to
evaluate if these FUT2 SNPs could be used as host biomarkers of
ETEC CFA/I (and related CFA/I CFs) infection susceptibility, or vac-
cine efficiency of ETEC vaccine candidates containing the CFA/I
antigen.
2.2. Secreted ETEC virulence proteins drive pathogen-host interactions
and contribute to clinical outcome
James Fleckenstein (Washington University School of Medicine,
St. Louis, Missouri) explained how his team is complementing their
host-pathogen interaction studies with genomics and related
‘‘omics” tools, to identify and characterise noncanonical ETEC vac-
cine candidates that are associated ETEC pathogenesis; i.e. novel
ETEC virulence factors associated with ETEC adhesion, intestinal
colonisation and toxin delivery during severe ETEC infection.
Initially, Dr Fleckenstein’s group performed a TnphoA
transposon-based mutagenesis study using the fully sequenced
human challenge ETEC H10407 strain, to identify secreted or
surface-expressed antigens. This study enabled the identification
of a number of novel ETEC plasmid-encoded virulence loci, includ-
ing the eatA autotransporter and the etpBAC two-partner secretion
system, that were expressed in the virulent ETEC H10407 strain,
but not in the fully sequenced E. coli K-12 strain [21,22]. Conse-
quently, EatA and EtpA are now being characterised to define their
suitability as ETEC vaccine components, as well as their contribu-
tion to disease in naturally infected hosts.
By combining genomic database mining and immunopro-
teomics, EatA has been found to be a member of the serine pro-
tease autotransporter family, as well as being fairly conserved
among a geographically and phylogenetically diverse group of
ETEC strains [23]. In addition, EatA has been found to be highly
immunogenic [24]. It has also been shown that EatA shares a high
degree of homology with SepA, a virulence protein secreted by Shi-
gella flexneri [21]. Moreover EatA has been found to degrade human
MUC2, a major intestinal mucin, expressed by goblet cells of the
human small intestine and colon [25]. Using an in-vitro enteroid
(human small intestinal derived stem cells) model [26], it has also
been observed that MUC2 degradation by EatA significantly
enhances ETEC LT or ST toxin delivery to host intestinal cell surface
receptors.
Likewise, EtpA has found to be a large glycosylated exoprotein,
secreted via the etpBAC two-partner secretion system (TPS) [22],
and acts as an adhesin molecule, forming a molecular bridge
between the tips of ETEC flagella and the host epithelial surface
[27]. Furthermore and similar to EatA, genomics and molecular
studies have demonstrated that EtpA appears to be conserved
among a diverse group of ETEC strains [23], as well as being highly
immunogenic [24].
Using a combination of human glycan arrays, biolayer inferom-
etry, noncanonical amino acid labelling and hemagglutination
studies, EtpA has been identified as a dominant ETEC blood group
A–specific lectin/hemagglutinin [28]. To demonstrate further that
this EtpA-blood group A mediated binding interaction enhances
ETEC pathogenesis, Dr Fleckenstein’s group has also used the bloodcs can be used to understand host susceptibility to enteric infection, aiding
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blood group A knockout HT-29A/ cells (derived by CRISPR-Cas9
engineering to eliminate the gene encoding blood group A glyco-
transferase) [29], as well as enteroids from blood group A individ-
uals, to demonstrate that EtpA-blood group A mediated interaction
significantly enhances bacterial adhesion ETEC LT and ST toxin
delivery [28].
Such molecular and genomic characterisation of EtpA has
enabled further collaborations with Dr Chakraborty (see Sec-
tion 2.3) to show that diarrhoeal illness following ETEC H10407
controlled human infection model (CHIM) challenge tends to be
significantly more severe in human blood group A volunteers than
volunteers with other blood group phenotypes [28,30].
2.3. Impact of host factors in preclinical diarrhoea outcome after
infection with ETEC in humans
In the third presentation, Subhra Chakraborty (Department of
International Health of the John Hopkins Bloomberg School of Pub-
lic health, Baltimore, MD) described how genomics is being used to
evaluate human host responses to ETEC during CHIM studies.
A total of 30 naive ETEC H10407 subjects were enrolled into a
CHIM study, in an inpatient unit at the Centre for Immunization
Research, John Hopkins University. These volunteers were ran-
domly assigned to one of two dosing groups; 105 or 106 colony-
forming unit (CFU) of ETEC strain H10407 (LT+ ST+ CFA/I+ and
O78+). Following the ETEC H10407 challenge, 29 out of the 30 vol-
unteers were found to shed ETEC bacteria. However, the rates of
moderate to severe diarrhoea (MSD) compared to asymptomatic
ETEC carriage varied between the volunteers of the same dosing
cohorts [30]. Subsequently, a comparison was made to compare
the results of MSD patients to asymptomatic ETEC shedders to
identify potential host biomarkers of severe diarrhoeal ETEC
illness.
Dr Chakraborty pre-screened the volunteers for pre-existing
ETEC antibody titres before ETEC H10407 challenge. This was per-
formed using antibodies in lymphocyte supernatants (ALS), sera
and faecal ELISA assays, and included; lipopolysaccharide (LPS)
IgA and IgG, LTB IgA and IgG, and CFA/I IgA and IgG analysis. Dr
Chakraborty compared subjects who subsequently developed
asymptomatic (n = 24) verses MSD (n = 6) subjects, and observed
only significantly higher pre-challenge LTB IgG antibody sera titres
(P = 0.02) in the asymptomatic subjects [31].
Next, Dr Chakraborty described the analysis that compared the
whole peripheral blood RNA expression profiles of MSD (n = 6) ver-
sus asymptomatic (n = 6) at the baseline time point [31]. DNA
Microarray (using the Affymetrix GeneChip Microarray Human
Genome U133A2.0) analysis was used to identify genes associate
with susceptibility to ETEC disease in these volunteers challenged
with ETEC H10407.
This microarray analysis identified 29 differentially expressed
gene probes that were potentially associated with resilience to sev-
ere ETEC infection. Of these 29 identified probes, gene probe sets
associated with major histocompatibility complex (MHC) protein
binding and MHC class I protein binding molecules were signifi-
cantly up-regulated in the asymptomatic dataset. The analysis also
identified four tubulin genes (Tubb2A, Tubb2b, Tubb3 and Tubb4B)
which have previously been associated with E. coli pathogenesis,
to be up-regulated in the asymptomatic (resilient to infection)
dataset. In comparison, C4BPA an inhibitor gene associated with
the classical complement pathway was down-regulated in the
asymptomatic (resilient to infection) dataset [31].
Dr. Chakraborty also described the 16S rRNA (ribosomal RNA)
gene sequencing gut microbiome analysis performed on stool spec-
imens from a subset of these ETEC H10407 infected individuals;
MSD (n = 5) and asymptomatic (n = 6) individuals. The aim of thisPlease cite this article as: L. Mottram, S. Chakraborty, E. Cox et al., How genomi
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to predict the onset of severe diarrheal ETEC disease [32].
Results from the 16S rRNA analysis revealed the MSD individu-
als (i.e. potential pre-infection microbiota predictors associated
with severe ETEC disease) had a higher concentration of faecal
Escherichia as well as Bacteroides dorei, Prevotella species, Alistipes
onderdonkii, Bacteroides species (ovatus), and Blautia species. In
contrast, the faecal microbiota of the asymptomatic carriers (i.e.
potential pre-infection microbiota predictors associated with resis-
tance against ETEC diarrhoeal disease) were enriched with nor-
malised 16S rRNA gene sequences including Sutterella species,
Prevotella copri, and Bacteroides vulgatus [32].
2.4. Genetic susceptibility of pigs to infections with enterotoxigenic
and shiga toxin producing E. coli
In the final presentation, Eric Cox (Ghent University, Belgium)
described the use of genomics and related genomic tools to exam-
ine the genetic susceptibility of pigs to F18+ fimbriae ETEC/shigella
toxin-producing E. coli (STEC) and F4+ fimbriae ETEC strains. The
susceptibility of pigs to F18+ and F4+ E. coli is determined by the
presence of F18 and F4 specific host receptors in the brush boarder
of pig’s small intestine. Therefore, understanding the genetic com-
position of these F18 and F4 host receptors is useful for animal
health and subsequent breeding management.
The functional pig F18+ E. coli intestinal binding receptor had
been previously thought to be only encoded by FUT1, a host gene
that encodes for a(1,2) fucosyltransferase blood group AO antigens
on small intestinal type 2 glycan chains in pigs. Meijerink et al. [33]
had demonstrated that a FUT1 SNP at nucleotide position bp307
(G=>A transition) of the FUT1 open reading farm (ORF) was closely
linked to susceptibility to F18+ E. coli infection, and thus genetic
variations in this FUT1 M307 SNP can be used as a specific genetic
marker for selecting and breeding pigs which are resistant to F18+
E. coli infections [33,34].
Conversely, Prof. Cox’s group has discovered that F18+ fimbriae
attach to the small intestine of young piglets by binding to mucosal
type 1 core glycans chains that express A/O blood group determi-
nants, with this host-pathogen interaction directly correlating with
F18+ E. coli infection susceptibility [35]. Subsequently, using struc-
tural and site directed mutagenesis studies it was defined that
FedF, the N-terminal domain subunit of F18 fimbriae is responsible
for F18+ E. coli binding to pig A and O blood groups [36,37].
Recent genetic studies have further identified that piglet sus-
ceptibility to F18+ E. coli infection might not be an absolute corre-
late with the FUT1M307 related SNP. Prof. Cox’s group is currently
analysing data to suggest the genetic regulation of FUT2 (a gene
closely related to FUT1), might also be controlling blood group A
and O blood expression in the pigs small intestine, and thus piglet
susceptibility to F18+ E. coli infection. Interestingly, the expression
of AO antigens in the pig’s small intestine is also directly correlate
with age, as Prof. Cox’s group has noticed that new-borns are
always resistant to F18+ E. coli infection independent of the FUT1
M307 SNP, and that susceptibility to F18+ E. coli infection becomes
highest just after weaning at 6–8 weeks old [38]. The mechanism
regulating this age-related expression is not known.
Prof. Cox also described the current work to genetically define
the F4+ ETEC fimbriae binding receptor in the porcine small intes-
tine. There are three antigenic variants of F4+ ETEC fimbriae (F4ab
+, F4ac+, F4ad+), with each antigenic variant showing a different
binding pattern to brush border membrane proteins of small
intestinal enterocytes. Only a small number of piglets completely
lack an intestinal receptor to F4+ ETEC fimbriae, and are therefore
resistant to F4+ bacteria and subsequent diarrhoea caused by F4+
ETEC strains. In Belgium however, most Flemish farmed pigs
express F4ab or F4ac intestinal receptors, so Flemish pigs are sub-cs can be used to understand host susceptibility to enteric infection, aiding
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infections [39].
Several studies located the F4ab/acR locus(loci) on chromosome
13 and several linkage studies proposed different loci as candidate
receptor loci such as the transferrin, the transferrin receptor
(TRFC), mucin 4 (MUC4), mucin 13 (MUC13), mucin 20 (MUC20),
solute carrier family 12 member 8 (SLC12A8), myosin light chain
kinase (MYLK), karyopherin alpha 1 (KPAN1), beclin-1 associated
RUN domain containing protein (KIAA0226), lactosylceramide 1,3-
N-acetyl-b-D-glucosaminyl transferase (B3GNT5) loci, but none of
the polymorphisms were found to be causative. Therefore, the
Gent University researchers conducted a GWAS study using 120
precisely F4ab/ac receptor phenotyped Flemish pigs (i.e. 52 F4ab
+/Fac+ E. coli resistant and 68 F4ab+/Fac+ E. coli susceptible pigs)
from 5 different Belgium farms, based on MUC4 and MUC13 poly-
morphism and in vitro villous adhesion of F4 = and F4ac+ E. coli.
DNA was isolated from the blood samples of these phenotyped pigs
and then sequenced using the Porcine SNP60 BeadChip (Illumina)
microarray [39,40].
This GWAS study revealed that pig F4ab/ac ETEC susceptibility,
is instead likely highly associated with two SNPs and genetic
regions adjacent to MUC13 (chr13: 144,810,100–144,993,222).
Unfortunately, these genetic regions lacks annotated genes, and
contain a sequence gap based on the sequence of the porcine Gen-
omeBuild 10.2. Subsequently, it can only be currently hypothesise
that a porcine orphan gene or trans-acting element in the candi-
date region determines F4ab/F4ac ETEC susceptibility in pigs
[40]. Prof. Cox therefore proposes further genetic and functional
annotation studies to identify the exact mechanisms and porcine
host receptor structures of F4ab/ac ETEC fimbriae.3. Summary of the group discussion
Following the presentations, the workshop moved to an open
discussion with attendees on how genomic and related genomic
tools could be best utilised to accelerate the current process of
ETEC and Shigella vaccine development.
To potentially aid the development of new vaccines, a good part
of the workshop discussion centred on the use of genomics during
molecular epidemiology studies. The assuming advantages of this
is that WGS or related high throughput genomic platforms could
be used to characterise the genomic diversity of the pathogen, as
well as take into account the genetic/immunological variability’s
of the host. Such information could be used to critically define
host-pathogen dynamics during infection, and thus define corre-
lates of protection.
For this to happen, some workshop attendees suggested such
studies would have to be large-scale multi country epidemiological
studies (e.g. similar to the scale of the GEMS study), where strong
population data and phenotypic information was collected on both
the pathogen and the host. To aid the subsequent identification of
any genomic host biomarker, associated with infection susceptibil-
ity, these epidemiological studies would also importantly need to
record the immune response elicited in each infected individual.
Another alternative option to using large-scale epidemiological
studies could be to use CHIM studies to define host-pathogen
dynamics during infection in a smaller number of individuals, in
a controlled environment [41]. Subsequent findings could then
be longitudinally evaluated in further field studies.
However, the workshop discussion emphasized that for geno-
mics analysis to be used efficiently in such molecular epidemiolog-
ical or CHIM studies, it would be important for both the ETEC and
Shigella scientific communities to harmonise which infection time
points are used to collect data related to immunological and geno-
mic analysis. Furthermore, to ensure that sample collection doesPlease cite this article as: L. Mottram, S. Chakraborty, E. Cox et al., How genomi
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important to standardise what human samples are collected, and
how they are collected and stored at both the epidemiological field
site or in the clinic.
Likewise, other workshop attendees suggested that WGS/NGS
can be used to fully annotate a group of ETEC or Shigella reference
strains that represent their worldwide geographical, temporal and
phenotypic diversity. It is well recognised the role played by the
erstwhile WHO reference laboratories, NIH, CDC, USDA as well
those such as the Sanger Institute in generating genomic databases
of Shigella and ETEC stains, who make reference strains/genomic
sequences available to the scientific community. However, perhaps
it could be advantageous to the ETEC and Shigella scientific com-
munities to work with a harmonised set of genomically annotated
ETEC and Shigella reference strains, as well as their related genomic
sequences. Such a harmonised, defined and fully sequenced strain
collection could be used in all the associated ETEC and Shigella vac-
cine developmental studies performed by different laboratories
worldwide.
The workshop speaker’s sessions highlighted how high
throughput genomic screening for virulence factors could offer
potential for the rational development of new vaccine candidates,
which could stand-alone or complement the vaccines currently
in development. Workshop attendees highlighted use of pro-
teomics [24] and the data mining of genomic or protein databases
[9], to aid the identification and characterisation of vaccine genes
or protein antigen candidates that play a key role in a pathogens
ability to infect and the hosts immune response. Equally, the
reverse vaccinology approach where comparative in-silico analysis
of multiple whole genome sequences are used to identify highly
conserved antigen in pathogenic strains but not commensal strains
was also mentioned as a successful method of vaccine discovery
[5].
Similarly, the group discussed the advantages of genomic anal-
ysis during preclinical in-vivo vaccine developmental studies. Ani-
mal studies are considered to be very important to evaluate
vaccine efficacy. However, some animal models never perfectly
correlate with the response in humans to ETEC or Shigella infection.
Subsequently, as well as using gene edited bacterial strains to char-
acterise vaccine antigen candidate expression and function, it was
discussed that genomics analysis could also be used to define
specific host-pathogen interactions during infection. Perhaps also,
genomics analysis could also be used in animal studies to assess
for the presence of a specific genetic biomarker that predict the
mucosal efficiency or toxicity of a vaccine, or even how effective
a vaccine would be in humans.
Others suggested the use of high throughput screens using large
scale sero-epidemiological studies [42] or gene-engineered knock-
out (e.g. using CRISPR/Cas9 and targeted genome engineering)
mammalian cells lines or mice, to identify host biomarkers genes
associated altered susceptibility to specific pathogenic antigens
[43–46]. In addition, genomics could be used to genetically define
small intestinal organoid or enteroid models to eliminate transla-
tion of results from animals to human models [26,47].
Following epidemiological studies, searches for antigens, in-
vitro and in-vivo modelling, a vaccine next goes into clinical trial.
Here the group discussed if genomics could also be used to
improve the process by identifying and testing for biomarkers that
alert researcher to toxicity or efficiency issues early in the clinical
trial process. Moreover, using GWAS studies, it may also possible to
identify the most genetically susceptible populations for a particu-
lar disease and thereby reduce the sample size needed for an effec-
tive trial, which could also reduce the cost of such clinical trials.
However, whilst the group felt this was important, it was consid-
ered that further research is still necessary to identify such defined
host biomarker(s) in the ETEC and Shigella fields.cs can be used to understand host susceptibility to enteric infection, aiding
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The workshop emphasised the importance of scientific interac-
tion among members of the ETEC and Shigella research communi-
ties, and the harmonisation and standardisation of efforts to
facilitate exchange of genomic sequencing, information and mate-
rials. The specific recommendations proposed from this workshop
are:
1. Genomics and related genomic applications can be used to
complement classical vaccinology approaches
2. To effectively use genomics and related technologies in ETEC
and Shigella vaccine development, immunological and genomic
sample collection time points should be standardised and har-
monized amongst different laboratories
3. The types of sample (i.e. saliva blood, faeces, PBMCs) collected
from the host for genomic related analysis should be standard-
ised, to avoid genomic skewing of data
4. To standardise genomic testing in the ETEC and Shigella scien-
tific communities, genomic collection and storage standard
operating procedures (SOPs) could be established for use
amongst the different ETEC and Shigella research groups
5. Establish a harmonised global set of genomically annotated
ETEC and Shigella reference strains for use in CHIM, vaccine
antigen discovery, and host-pathogen interaction studies
6. Use genomics to aid the development of more genetically
defined humanised models for use in ETEC and Shigella patho-
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